secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001935979-25-000026
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development
--------------------------------------------------------------------------------

- First tranche $250M funded at closing on or before April 30, 2025.
- Second tranche up to $150M available upon FDA approval of troriluzole; third tranche up to $200M for acquisitions.
- Oberland receives tiered single-digit royalties on global troriluzole net sales for up to 10 years, capped at multiples.
- Additional milestone payment of 35% of funded amount upon FDA or EMA approval.
- Proceeds to support ongoing clinical trials and commercialization preparations for troriluzole in SCA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/0001935979-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/bhvn-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer